Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BEAM

Beam Therapeutics Inc

Feb 10 • 10:30AM ET

27.66

+0.38 1.39 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK XBI VTI IWM ARKG VB VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-4.43	Insider Own	9.81%	Shs Outstand	101.36M	Perf Week	-0.82%
Market Cap	2.81B	Forward P/E	-	EPS next Y	-4.67	Insider Trans	-1.37%	Shs Float	91.52M	Perf Month	0.40%
Enterprise Value	1.88B	PEG	-	EPS next Q	-1.00	Inst Own	98.86%	Short Float	21.90%	Perf Quarter	24.54%
Income	-414.64M	P/S	50.39	EPS this Y	8.62%	Inst Trans	-3.60%	Short Ratio	10.73	Perf Half Y	61.14%
Sales	55.70M	P/B	2.90	EPS next Y	-11.54%	ROA	-33.41%	Short Interest	20.04M	Perf YTD	-0.22%
Book/sh	9.53	P/C	2.61	EPS next 5Y	-1.27%	ROE	-47.19%	52W High	36.44 -24.09%	Perf Year	0.91%
Cash/sh	10.59	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-37.53%	52W Low	13.52 104.51%	Perf 3Y	-42.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	60.38%	Volatility	7.66% 8.36%	Perf 5Y	-72.20%
Dividend TTM	-	EV/Sales	33.81	EPS Y/Y TTM	-157.71%	Oper. Margin	-837.12%	ATR (14)	2.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.02	Sales Y/Y TTM	-84.07%	Profit Margin	-744.41%	RSI (14)	46.81	Recom	1.28
Dividend Gr. 3/5Y	- -	Current Ratio	6.02	EPS Q/Q	6.31%	SMA20	-7.44%	Beta	2.13	Target Price	46.53
Payout	-	Debt/Eq	0.16	Sales Q/Q	-32.03%	SMA50	-2.37%	Rel Volume	0.49	Prev Close	27.28
Employees	483	LT Debt/Eq	0.14	Earnings	Nov 04 BMO	SMA200	23.09%	Avg Volume	1.87M	Price	27.66
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.99% -14.46%	Trades		Volume	181,163	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117

Show Previous Ratings

Jan-29-26 07:17AM	Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) (Insider Monkey)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 04:15PM	Beam Soars 22% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily) +22.29%
03:37PM	Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference (MarketBeat)
01:39PM	Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? (Benzinga)
12:54PM	Loading…
12:54PM	Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition (GlobeNewswire)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.59%
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:46PM	Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene (Insider Monkey)
07:33AM	Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
06:50AM	Loading…
Dec-22-25 06:50AM	BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy (Insider Monkey) +5.08%
Dec-18-25 04:01PM	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-06-25 08:00AM	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks) +8.12%
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.82%
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga)
07:00AM	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-25 08:16PM	Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Loading…
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
Nov-04-25 03:37PM	Cathie Wood unloads $7.69 million in top AI stock (TheStreet) -6.23%
03:37PM	Cathie Wood sells another $7.69 million in leading AI stock (TheStreet)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
09:00AM	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks) +5.08%
01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
Oct-30-25 12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks) -6.28%
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:55AM	Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-25 09:55AM	Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +17.86%
09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans John M.	CEO	Jan 29 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 29 '26	Sale	29.38	25,000	734,582	986,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Sale	28.36	25,000	708,946	986,667	Feb 02 04:05 PM
JOHN M EVANS	Officer	Jan 30 '26	Proposed Sale	28.36	25,000	708,948		Jan 30 04:04 PM
JOHN M EVANS	Officer	Jan 29 '26	Proposed Sale	29.38	25,000	734,582		Jan 29 04:01 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 22 '26	Sale	35.00	6,198	216,933	34,813	Jan 26 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 22 '26	Sale	34.00	1,371	46,614	95,667	Jan 26 04:05 PM
CHRISTINE BELLON	Officer	Jan 22 '26	Proposed Sale	34.00	1,371	46,614		Jan 22 04:03 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 20 '26	Sale	30.12	3,034	91,384	41,011	Jan 21 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 15 '26	Sale	34.61	18,629	644,832	97,038	Jan 20 04:05 PM
CHRISTINE BELLON	Officer	Jan 15 '26	Proposed Sale	34.61	18,629	644,831		Jan 15 06:00 PM
Emany Sravan Kumar	Chief Financial Officer	Dec 31 '25	Sale	27.10	6,294	170,567	73,706	Jan 05 04:16 PM
Bellon Christine	Chief Legal Officer	Dec 31 '25	Sale	27.10	1,254	33,983	115,667	Jan 05 04:12 PM
FMR LLC	See Remark 1	Oct 27 '25	Sale	26.68	459	12,246	14	Oct 29 01:13 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '25	Sale	24.53	467	11,456	44,045	Oct 03 04:15 PM
Bellon Christine	Chief Legal Officer	Oct 01 '25	Sale	24.53	373	9,150	116,921	Oct 03 04:10 PM
Evans John M.	CEO	Oct 01 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Sale	24.63	25,000	615,668	986,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 01 '25	Sale	24.51	25,000	612,655	986,667	Oct 03 04:05 PM
JOHN M EVANS	Officer	Oct 02 '25	Proposed Sale	24.63	25,000	615,668		Oct 02 04:23 PM
JOHN M EVANS	Officer	Oct 01 '25	Proposed Sale	24.51	25,000	612,655		Oct 01 04:12 PM
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Option Exercise	7.22	10,000	72,200	112,968	Feb 19 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Sale	34.00	10,000	340,000	102,968	Feb 19 04:10 PM
CHRISTINE BELLON	Officer	Feb 14 '25	Proposed Sale	34.00	10,000	340,000		Feb 14 04:06 PM

Open in Screener

SANA

Sana Biotechnology Inc

Feb 10 • 10:30AM ET

4.07

+0.07 1.63 %

Healthcare • Biotechnology • USA • NASD

SANA Sana Biotechnology Inc daily Stock Chart

Peers: VERV PRME NTLA EDIT TSHA CRBU CABA BEAM MGTX PGEN

| Held by: VTI XBI IWM VXF IWN IBB VTWO SCHA VHT PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.97	Insider Own	37.73%	Shs Outstand	262.26M	Perf Week	-7.82%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	165.85M	Perf Month	-10.86%
Enterprise Value	1.01B	PEG	-	EPS next Q	-0.14	Inst Own	47.70%	Short Float	22.38%	Perf Quarter	-0.61%
Income	-234.41M	P/S	-	EPS this Y	25.60%	Inst Trans	4.94%	Short Ratio	9.90	Perf Half Y	39.21%
Sales	0.00M	P/B	5.46	EPS next Y	35.22%	ROA	-47.13%	Short Interest	37.11M	Perf YTD	-0.12%
Book/sh	0.74	P/C	6.89	EPS next 5Y	19.30%	ROE	-96.11%	52W High	6.55 -37.94%	Perf Year	35.95%
Cash/sh	0.59	P/FCF	-	EPS past 3/5Y	18.55% -10.60%	ROIC	-89.07%	52W Low	1.26 222.62%	Perf 3Y	-13.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.77% 7.55%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.16%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.40	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.55	EPS Q/Q	36.45%	SMA20	-9.66%	Beta	1.97	Target Price	8.17
Payout	-	Debt/Eq	0.42	Sales Q/Q	-	SMA50	-10.12%	Rel Volume	0.47	Prev Close	4.00
Employees	194	LT Debt/Eq	0.35	Earnings	Nov 06 AMC	SMA200	9.92%	Avg Volume	3.75M	Price	4.07
IPO	Feb 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.25% -	Trades		Volume	346,051	Change	1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	Wedbush	Outperform	$5
Jul-03-25	Resumed	Morgan Stanley	Overweight	$12
Mar-18-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Mar-14-25	Initiated	Jefferies	Buy	$7
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy	$16
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Sep-25-23	Initiated	JMP Securities	Mkt Outperform	$9
Sep-05-23	Initiated	Citigroup	Buy	$8
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight	$40
Mar-01-21	Initiated	JP Morgan	Neutral	$35
Mar-01-21	Initiated	Goldman	Neutral	$40
Mar-01-21	Initiated	BofA Securities	Buy	$45

Show Previous Ratings

Jan-30-26 12:00PM	Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know (Zacks)
Jan-23-26 09:55AM	Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet (Zacks)
Jan-07-26 04:26PM	Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.49%
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +7.39%
Dec-28-25 10:05AM	Sana Biotechnology Showcases Successful In Vivo Gene Editing of Stem Cells in Nature Publication (Insider Monkey)
09:00AM	Loading…
Dec-08-25 09:00AM	Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform (GlobeNewswire) -9.75%
Nov-28-25 10:11AM	Sana (SANA) Surges 14.5% Ahead of Business Announcements (Insider Monkey) +6.97%
Nov-24-25 04:05PM	Sana Biotechnology to Present at December 2025 Investor Conferences (GlobeNewswire) +7.60%
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
06:17AM	Sana Biotechnology (SANA) Wins Analyst Support With Strategic Focus and Cash Strength (Insider Monkey)
Nov-12-25 12:00PM	All You Need to Know About Sana (SANA) Rating Upgrade to Buy (Zacks)
Nov-06-25 04:26PM	Sana: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:05PM	Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) -9.19%
Oct-15-25 12:07PM	Progressive stock sinks on Q3 miss, gold hits yet another record (Yahoo Finance Video) +33.03%
10:45AM	Loading…
10:45AM	Sana Biotechnology stock higher after Eric Jackson touts 100-bagger potential (Investing.com)
Sep-20-25 02:43AM	Sana Biotechnology Inc. (SANA) Bolsters Management Team (Insider Monkey)
Sep-17-25 02:18PM	Can Sana Biotechnology's (SANA) Pipeline Momentum Translate into More Share Price Upside? (Insider Monkey)
Sep-15-25 07:30AM	3 Stocks to Buy Under $10 That Could Triple From Here (Barchart)
Sep-08-25 12:30AM	JMP Securities Keeps Market Outperform Rating on Sana Biotechnology (SANA) (Insider Monkey)
Aug-26-25 04:05PM	Sana Biotechnology to Present at September 2025 Investor Conferences (GlobeNewswire)
Aug-25-25 11:56PM	Citizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PT (Insider Monkey) -6.42%
Aug-20-25 04:05PM	Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-12-25 11:43AM	Sana Biotech Bails on Factory in Old AT&T Call Center (IEN) +6.51%
Aug-11-25 06:11PM	Sana: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -30.12%
Aug-06-25 11:24PM	Sana Biotechnology Announces Pricing of Public Offering (GlobeNewswire)
04:38PM	Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:00AM	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
11:35AM	Loading…
Aug-04-25 11:35AM	Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes (GlobeNewswire) +8.18%
Aug-01-25 06:47AM	Sana Biotechnology (SANA) Rated 'Market Perform' on Diabetes Program Prospects (Insider Monkey)
Jul-31-25 11:40PM	Citi Remains Bullish on Sana Biotechnology (SANA) (Insider Monkey) -6.88%
Jul-23-25 11:25AM	Citi Maintained a Buy Rating on Sana Biotechnology (SANA) (Insider Monkey) +5.54%
Jul-11-25 07:11PM	Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley (Insider Monkey)
Jul-03-25 09:09AM	Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting (Insider Monkey) +9.25%
Jun-24-25 03:51PM	BofA Remains Bullish on Sana Biotechnology (SANA) (Insider Monkey) +14.23%
Jun-23-25 10:05AM	Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression (GlobeNewswire)
Jun-09-25 04:05PM	Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire)
May-28-25 04:05PM	Sana Biotechnology to Present at June 2025 Investor Conferences (GlobeNewswire) +12.50%
May-12-25 04:05PM	Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference (GlobeNewswire) +9.89% -10.25%
May-08-25 04:42PM	Sana: Q1 Earnings Snapshot (Associated Press Finance) +6.47%
04:05PM	Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-06-25 10:12PM	Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development (PR Newswire) -8.56%
Apr-29-25 08:00AM	Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics (PR Newswire)
Apr-24-25 06:00AM	Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare (PR Newswire)
Apr-22-25 05:45AM	Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA (PR Newswire) +8.81%
Apr-21-25 12:56PM	Sana Biotechnology, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights SANA (GlobeNewswire)
Apr-16-25 11:23AM	Is Sana Biotechnology Inc. (NASDAQ:SANA) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -7.06%
Apr-10-25 12:39PM	Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights SANA (GlobeNewswire)
Apr-01-25 08:00AM	Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease (PR Newswire) -10.71%
Mar-25-25 08:00AM	Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform (Business Wire) -11.16%
Mar-24-25 11:45PM	Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421 (SeekingAlpha)
Mar-17-25 04:14PM	Sana: Q4 Earnings Snapshot (Associated Press Finance) -5.46% -17.69%
04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:04PM	Is Sana Biotechnology (SANA) Among Jeff Bezos Investments in 2025? (Insider Monkey) +5.35%
Mar-01-25 06:02PM	Why Sana Biotechnology, Inc. (SANA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-24-25 04:05PM	Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference (GlobeNewswire) -10.07%
Jan-28-25 10:42AM	Sana Biotechnology, Inc. (SANA): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:59AM	Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025? (Insider Monkey) +19.86%
Jan-08-25 04:05PM	Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +160.61% -14.88%
10:34AM	Sana Biotechnology (SANA), eBay (EBAY) Are Among Todays Big Winners (Insider Monkey)
10:11AM	This Biotech Stock Soared 300% Overnight. Why It Can Go Higher. (Barrons.com)
07:26AM	Sana Biotechnology price target lowered to $7 from $8 at BofA (TipRanks)
07:25AM	This Biotech Stock Just Soared 240%. Why It Can Go Higher. (Barrons.com)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 04:05PM	Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression (GlobeNewswire) -5.71%
Dec-02-24 09:00AM	Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus (GlobeNewswire)
Nov-25-24 04:05PM	Sana Biotechnology to Present at December 2024 Investor Conferences (GlobeNewswire)
Nov-20-24 08:00AM	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies (PR Newswire) +7.20%
06:30AM	Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer (PR Newswire)
Nov-13-24 09:55AM	Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher (Zacks) -6.34%
08:00AM	Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio (PR Newswire)
08:00AM	Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner (PR Newswire)
Nov-11-24 09:35AM	Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 09:10AM	Sana: Q3 Earnings Snapshot (Associated Press Finance)
09:00AM	Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-05-24 04:40AM	Sana to lay off staff, deepen autoimmune focus in latest retrenchment (BioPharma Dive) -9.84%
Nov-04-24 04:30PM	Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 (GlobeNewswire)
Oct-23-24 08:00AM	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence (PR Newswire)
Oct-16-24 08:58AM	Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts (Insider Monkey)
Oct-13-24 04:48PM	Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Oct-09-24 07:00AM	Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions (PR Newswire)
Oct-03-24 08:00AM	Invaio Sciences Appoints Andr Andonian as Chairman of the Board of Directors (PR Newswire)
Sep-30-24 04:05PM	Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 06:00AM	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry (PR Newswire) +13.56%
Aug-29-24 04:05PM	Sana Biotechnology to Present at September 2024 Investor Conferences (GlobeNewswire)
Aug-28-24 06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
Aug-26-24 04:05PM	Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 05:03PM	Sana: Q2 Earnings Snapshot (Associated Press Finance) +5.36%
04:05PM	Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-06-24 06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-23-24 06:00AM	Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire) -7.00%
Jul-10-24 06:00AM	Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability (PR Newswire)
06:00AM	Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions (PR Newswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
May-21-24 09:00AM	Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other Glial-based Neurodegenerative Conditions (GlobeNewswire)

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wyrick Susan D.	See Remarks	Jan 02 '26	Option Exercise	0.00	7,500	0	188,290	Jan 06 04:18 PM
Wyrick Susan D.	See Remarks	Dec 13 '25	Option Exercise	0.00	3,400	0	181,663	Dec 16 04:16 PM
Wyrick Susan D.	See Remarks	Dec 03 '25	Option Exercise	0.00	10,000	0	180,828	Dec 05 05:04 PM
Wyrick Susan D.	See Remarks	Jun 03 '25	Option Exercise	0.00	10,000	0	170,395	Dec 05 05:04 PM
Wyrick Susan D.	See Remarks	Mar 07 '25	Option Exercise	0.00	3,250	0	158,231	Mar 10 08:13 PM
Cassidy Bernard J	EVP & General Counsel	Mar 07 '25	Option Exercise	0.00	11,041	0	115,823	Mar 10 08:12 PM
Harr Steve	President & CEO	Mar 07 '25	Option Exercise	0.00	50,000	0	7,889,750	Mar 10 08:12 PM
Wyrick Susan D.	See Remarks	Mar 02 '25	Option Exercise	0.00	1,525	0	155,471	Mar 03 07:28 PM
CHRISTIAN HORDO & KATHARINE HO	Officer	Feb 18 '25	Proposed Sale	3.16	75,000	237,000		Feb 18 04:27 PM

BEAM

Beam Therapeutics Inc

SANA

Sana Biotechnology Inc

Upgrade your FINVIZ experience